Replies to post #13047 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Is it possible altering the fucose may increase the affinity of antibody for the target cell?<

To my knowledge, no company is touting a fucosylation-related benefit in a mAb’s affinity for its binding site, so the answer to your is presumably No.


Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

[Lewis R Goudy]

Jesse it's correct that mannosylation at Asn257 can serve to
enhance ADCC but assuming that is what Dr Meade was referring
to you are mistaken that CHO cannot enjoy that type of engineering. cf
http://www.freepatentsonline.com/y2007/0092521.html

>I did get the distinct impression from Dr. M. that the binding the NK cells is the most important action.

I don't doubt that at all. The citation mentions
another case where the apportionment of ADCC enhancement
between two alterations is controversial (fucose vs N-acetyl-glucosamine).

I am glad to be having this little chat because it reminds us
that our glycosylation characteristics are fundamental positives,
slide bullets in their own right, sometimes overshadowed
in the investment narrative.